TY - JOUR
T1 - The impact of triple drug immunosuppression on clinical results of cadaveric kidney transplantation
T2 - a comparison of conventional immunosuppression.
AU - Sakagami, K.
AU - Saito, S.
AU - Shiozaki, S.
AU - Takasu, S.
AU - Matsuno, T.
AU - Fujiwara, T.
AU - Kusaka, S.
AU - Uda, M.
AU - Matsuoka, J.
AU - Naomoto, Y.
PY - 1992/2
Y1 - 1992/2
N2 - A retrospective study was carried out in 110 cadaveric kidney transplant recipients to compare the effects of low doses of cyclosporine (CsA), azathioprine (AZP) and steroids (triple-drug therapy) with those of higher doses of steroids plus AZP (conventional immunosuppression). Graft survival rate in the triple-drug therapy was 77%, 69%, and 69% at 1, 3, and 5 years, respectively. This was significantly better than 48%, 34%, and 29% in conventional immunosuppression. The incidence of acute rejection episodes was significantly lower in the triple-drug therapy than in conventional immunosuppression (25% vs 58%). In conclusion, our study shows that triple-drug therapy using low-dose cyclosporine is the safest of the immunosuppressive regimens and provides a beneficial effect on the long-term survival of cadaveric kidney transplants.
AB - A retrospective study was carried out in 110 cadaveric kidney transplant recipients to compare the effects of low doses of cyclosporine (CsA), azathioprine (AZP) and steroids (triple-drug therapy) with those of higher doses of steroids plus AZP (conventional immunosuppression). Graft survival rate in the triple-drug therapy was 77%, 69%, and 69% at 1, 3, and 5 years, respectively. This was significantly better than 48%, 34%, and 29% in conventional immunosuppression. The incidence of acute rejection episodes was significantly lower in the triple-drug therapy than in conventional immunosuppression (25% vs 58%). In conclusion, our study shows that triple-drug therapy using low-dose cyclosporine is the safest of the immunosuppressive regimens and provides a beneficial effect on the long-term survival of cadaveric kidney transplants.
UR - http://www.scopus.com/inward/record.url?scp=0026810253&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026810253&partnerID=8YFLogxK
M3 - Article
C2 - 1561907
AN - SCOPUS:0026810253
SN - 0386-300X
VL - 46
SP - 53
EP - 56
JO - Acta medica Okayama
JF - Acta medica Okayama
IS - 1
ER -